Alira Health and HTAi Collaborate to Develop a Multi-Stakeholder Value Assessment Framework for Robotic-Assisted Surgery & Digital Health

Alira Health, a global healthcare consulting and technology firm with expertise in Health Technology Assessment (HTA) methodology, will coordinate the discussion and consensus of evidence-based guidance on HTA for Robotic-Assisted Surgery (RAS) and Digital Health Technologies.

This multi-stakeholder Value Assessment Framework will provide guidance on how to overcome challenges in determining the cost-effectiveness of robotic-assisted surgery from the perspectives of patients, physicians, and payers.

The framework, designed in collaboration with the HTAi Medical Device Interest Group, is technology and company agnostic. Key areas of guidance will include:

  • best practices in assessing the value of robotic-assisted surgery at both the national and hospital level;
  • how to support the implementation of RAS and Digital Health programs globally;
  • how to ensure the clinician and patient perspectives are included in the quantification of value.

The following areas of consensus will be sought from a panel of leading robotic-assisted surgeons, leading health economists, and policymakers:

  • Clinical Challenges
    • Evidence type and quality (RCT vs RWE)
    • Physician and patient-reported outcomes
    • Physician learning curve
  • Economic Challenges
    • Appropriate Time Horizon for evaluation
    • Challenges of a high upfront capital investment
    • Organizational impact on surgical procedures
  • Digital Challenges
    • Evaluation of an increasingly digitally-enabled RAS ecosystem
    • Overcoming the rapid evolution of digital solutions
Published on:
March 22, 2022
"The guidance will be aimed at HTA agencies globally and will allow them to better assess the value of robotic surgical and digital health systems. We are pleased to be overseeing the operation of such a crucial project and contributing to the development of the consensus document and scientific publication with the recommendations for HTA agencies."
Richard Charter Vice President MedTech Market Access - Europe & Asia Pacific at Alira Health

About Alira Health

Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.

Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.

About HTAi

Health Technology Assessment international (HTAi) is the global, non-profit, scientific, and professional society for all those who produce, use or encounter health technology assessment (HTA). The society represents 82 organizations and over 2,500 individual members from 65 countries around the world.

Related news

Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
News April 5, 2023
Alira Health Joins EMIG to Advance Market Access in the UK
We are pleased to announce that Alira Health has joined the Ethical Medicines Industry Group (EMIG), a multi-stakeholder network and trade association that represents the interests(...)
Market Access Patient Centricity UK
Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Italy Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence (RWE)
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.